Health-related quality of life in patients with endocrine tumours of the gastrointestinal tract

Acta Oncologica

Volumn 38, Issue 4, 1999, Pages 481-490

  Larsson, Gunnel ^a,b   Von Essen, Louise ^a   Sjödén, Per Olow ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAN1 INTERFERON; FINFERON; OCTREOTIDE; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERFERON; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ANXIETY; ARTICLE; DEPRESSION; DIARRHEA; ENDOCRINE TUMOR; FEMALE; GASTROINTESTINAL TUMOR; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SOCIAL STATUS;

ADULT; AGED; AGED, 80 AND OVER; ANXIETY; DEPRESSION; ENDOCRINE GLAND NEOPLASMS; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; RETROSPECTIVE STUDIES;

EID: 0032977113     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418699432022     Document Type: Article

References (37)

1. 1. Öberg K. Endocrine tumors of the gastrointestinal tract: systemic treatment. Anti-Cancer Drugs 1994; 5: 503-19.
2. 2. Wilander E, Lundqvist ML, Öberg K. Gastrointestinal carcinoid tumors. In: Graumann W, Lojda Z, Pearse AGE, Schiebler TH, eds. Progress in histochemistry and cytochemistry. Stuttgart; Gustav Fischer Verlag, 1989: 2-19.
3. 3. Öberg K, Eriksson B. Medical treatment of neuroendocrine gut and pancreatic tumours. Acta Oncol 1989; 28: 425-31.
4. 4. Öberg K. Interferon therapy of neuroendocrine tumours. In: Aul C, Schneider W, eds. Interferons: Biological activities and clinical efficacy. Berlin: Springer, 1997: 36-46.
5. 5. Aaronson NK, Cull A, Kaasa S, Sprangers M. The EORTC modular aproach to quality of life assessment in oncology. Int J Mental Health 1994; 23: 75-96.
6. 6. Shumaker SA, Naughton MJ. The international assessment of health-related quality of life: a theoretical perspective. In: Shumaker SA, Bernzon R, eds. The International Assessment of Health-related quality of life: theory, translation, measurement and analysis. Oxford: Rapid Communications of Oxford, 1995: 3-10.
7. 7. Faithfull S. Just grin and bear it and hope that it will go away': coping with urinary symptoms from pelvic radio therapy. Eur J Cancer Care 1996; 4: 158-65.
8. 8. Montgomery H, Johansson US. Life values: their structure and relation to life situation. In: Maital S, ed. Applied behavioral economics. Brighton: Wheatsheal, 1988; 420-37.
9. 9. Öberg K. Chemotherapy and biotherapy in neuroendocrine tumors. Curr Opin Oncol 1993; 5: 110-20.
10. 10. Öberg K, Eriksson B, Tiensuu JE. Interferons alone or in combination with chemotherapy or other biologicals in the treatment of neuroendocrine gut and pancreatic tumors. Digestion 1994; 55: 64-9.
11. 11. Larsson G, von Essen L, Sjödén PO. Quality of life in patients with endocrine tumours of the gastrointestinal tract: patient and staff perceptions. Accepted for publication in Cancer Nurs 1998; 21: 6.
12. 12. Jacobsen MB, Hanssen LE. Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial. J Int Med 1995; 237: 269-75.
13. 13. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ C30: a quality-of-life instrument for use in international clinical trials in oncology. J Nat Cancer Inst 1993; 85: 365-76.
14. 14. Sprangers MAG, Cull A, Bjordal K, Groenvold M, Aaronson NK. The European Organization for Research and Treatment of Cancer approach to quality of life assessment: guidelines for developing questionnaire modules. Quality of Life Res 1993; 2: 287-95.
15. 15. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67: 361-70.
16. 16. Ibbotson T, Maguire P, Selby P, Priestman T, Wallace L. Screening for anxiety and depression in cancer patients: the effects of disease and treatment. Eur J Cancer 1994; 1: 37-40.
17. 17. Moorey S, Greer S, Watson M, et al. The factor structure and factor stability of the Hospital Anxiety and Depression Scale in patients with cancer. Br J Psychiatry 1991; 158: 255-9.
18. 18. Lampic C, von Essen L, Widmark-Peterson V, Larsson G, Sjödén PO. Anxiety and depression in hospitalized patients with cancer: agreement in patient staff dyads. Cancer Nurs 1996; 19: 419-28.
19. 19. Carlsson M, Hamrin E. Measurement of quality of life in women with breast cancer. Development of a Life Satisfaction Questionnaire (LSQ 32) and comparison with the EORTC QLQ C30. Quality of Life Res 1996; 5: 265-74.
20. 20. Bjordal K, Freng A, Thorvik J, Kaasa S. Patients' self-reported and clinician-rated quality of life in head and neck cancer patients: a cross-sectional study. Oral Oncol Eur J Cancer 1995; 4: 235-41.
21. 21. Blazeby JM, Williams MH, Brookes ST, Alderson D, Farndon JR. Quality of life measurement in patients with oesophageal cancer. Gut 1995; 37: 505-8.
22. 22. Glimelius B, Hoffman K, Sjödén PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600.
23. 23. Maher EJ, Mackenzie C, Young T, Marks D. The use of the Hospital Anxiety and Depression Scale (HADS) and the EORTC QLQ C30 questionnaires to screen for treatable unmet needs in patients attending routinely for radiotherapy. Cancer Treat Rev 1996; 22: 123-9.
24. 24. Klee M, Groenvold M, Machin D. Quality of life of Danish women: population-based norms for the EORTC QLQ C30. Quality of Life Res 1997; 6: 27-34.
25. 25. Wisloff F, Hjort M, Kaasa S, Westin J. Effect of Interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melpheran prednisone to melpheran prednisone + α-interferon. Br J Haematology 1996; 94: 324-32.
26. 26. Batey MV, Acquiescent response set: a source of measurement error. Western J Nurs Res 1979; 1: 247-9.
27. 27. Sutherland HJ, Lockwood GA, Boyd NF. Ratings of the importance of quality of life variables: therapeutic implications for patients with metastatic breast cancer. J Clin Epidemiol 1990; 43: 661-6.
28. 28. von Essen L, Burström L, Sjödén PO. Perceptions of caring behaviors and patient anxiety and depression in cancer patient - staff dyads. Scand J Car Sci 1994; 8: 205-12.
29. 29. Hopwood P, Howell A, Maguire P. Psychiatric morbidity in patients with advanced cancer of the breast: prevalence measured by two self-rating questionnaires. Br J Cancer 1991; 64: 349-52.
30. 30. de Haes JCJM, van Knippenberg FCE, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990; 62: 1034.
31. 31. Morris T. Psychosocial aspects of breast cancer: a review. J Clin Oncol 1983; 19: 1725-33.
32. 32. Morris T, Greer S, White P. Psychological and social adjustment to mastectomy: a two-year follow-up study. Cancer 1977; 40: 2381-8.
33. 33. Rodriguez JR, Behen JM, Tumlin T. Multidimensional determinants of psychological adjustment to cancer. Psycho-Oncol 1994; 3: 205-14.
34. 34. Sprangers M. Response-shift bias: a challenge to the assessement of patients' quality of life in cancer clinical trials. Cancer Treat Rev 1996; 22: 55-62.
35. 35. Herrmann C. International experiences with the Hospital Anxiety and Depression Scale - a review of validation data and clinical results. J Psychosom Res 1997; 42: 17-41.
36. 36. Osoba D, Zee B, Pater J, Warr D, Kalzer L, Latreille J. Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ C30) in patients with breast, ovarian and lung cancer. Qual Life Res 1994; 3: 353-64.
37. 37. Ringdal GI, Ringdal K. Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnoses. Qual Life Res 1993; 2: 129-40.